TY - JOUR
T1 - Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation
AU - Nakajima, Hideyuki
AU - Kamata, Masahiro
AU - Okada, Yoshiki
AU - Ito, Makoto
AU - Watanabe, Ayu
AU - Azuma, Saori
AU - Uchida, Hideaki
AU - Egawa, Shota
AU - Chijiwa, Chika
AU - Hiura, Azusa
AU - Fukaya, Saki
AU - Hayashi, Kotaro
AU - Fukuyasu, Atsuko
AU - Tanaka, Takamitsu
AU - Ishikawa, Takeko
AU - Sugiura, Kazumitsu
AU - Tada, Yayoi
N1 - Publisher Copyright:
© 2024 JLE.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].
AB - Generalized pustular psoriasis (GPP) is a rare, recurrent, and sometimes life-threatening skin disease with systemic inflammation characterized by erythema and sterile pustules over the entire body, accompanied by acute fever and vascular hyperpermeability. Although biologics including interleukin (IL)-17 inhibitors are available for the treatment of GPP in some countries [1, 2], treatment options are still limited. Spesolimab, an anti-IL-36 receptor antibody, showed significant efficacy with tolerable [...].
UR - https://www.scopus.com/pages/publications/85199014525
UR - https://www.scopus.com/pages/publications/85199014525#tab=citedBy
U2 - 10.1684/ejd.2024.4711
DO - 10.1684/ejd.2024.4711
M3 - Letter
C2 - 39015980
AN - SCOPUS:85199014525
SN - 1167-1122
VL - 34
SP - 324
EP - 325
JO - European Journal of Dermatology
JF - European Journal of Dermatology
IS - 3
ER -